European Medicines Agency ’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Dateline City:
KENILWORTH, N.J. Recommendation Is for Adult Patients Who Have Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who Are Transplant-Ineligible and Have Failed BVKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of KEYTRUDA® (pembrolizumab),
the company ’s anti-PD-1 therapy, for the treatment of adult patients
with relapsed or refractory classical Hodgkin lymphoma (cHL)who
have failed autologous stem cell transplant (ASCT) and brentuximab
vedotin (BV), or who are transplant-ineligibLanguage:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NYSE:MRK Source Type: news
More News: Cancer & Oncology | Drugs & Pharmacology | European Medicines Agency (EMA) | Lymphoma | Merck | Stem Cell Therapy | Stem Cells | Transplants